State medication access · Selected providers
Tirzepatide: online access in the District of Columbia.
Company statements checked September 10, 2026: 1 covered company — Gentle Health — advertises online access to Tirzepatide for patients in the District of Columbia. Confirm eligibility and total charges with the provider.
Company-reported District of Columbia access to Gentle Health's compounded injectable tirzepatide program, with product, first-visit and payment limitations.
Selected product offers advertised for patients in the District of Columbia, not verified local offices, pharmacy stock, appointment slots or prescription guarantees.
Keep the product attached to the price
Gentle Health’s District of Columbia coverage concerns compounded injectable tirzepatide. After adding Missouri on September 18, the article described a footprint of 40 states plus the District. This entry rests on a list that includes the District rather than on a nationwide sentence. The monthly price belongs to that one program, not to an oral preparation or to every tirzepatide product.
A compounded preparation is not an approved generic, and it is not branded Zepbound or Mounjaro. FDA describes this distinction; an ingredient listing is not an equivalence claim.
Confirm the first-visit route
The August 21 workflow article sorts jurisdictions between intake-review-first and scheduled-video routes. The company’s workflow article lists Washington, DC among the jurisdictions where the first visit starts asynchronously, with a questionnaire reviewed by a clinician rather than a scheduled video call. That describes the company’s stated process, not a guarantee: a clinician can still ask for a live conversation, and you should confirm the required steps before paying. Ask which steps apply here. A clinician may still request more information, require a live visit or decline; this describes company operations, not local law.
Check the price and the cancellation terms
Gentle Health advertises compounded injectable tirzepatide at $169, $219 or $269 monthly, without a separate membership fee. Its current terms say the first medication request starts a recurring monthly subscription. Cancellation is available before pharmacy submission or beginning 30 days after the order date once submitted; it stops future billing immediately, but the current billing month’s remainder is not refunded. Pharmacy-stage refunds are handled case by case.
Individual approval and pharmacy stock remain unverified. Check the actual order terms, then use the Gentle Health profile and the broader tirzepatide guide for company and product context.
Compare prices
All-in cost for the first 12 weeks at each covered provider, including membership and medication fees, commitments and renewal terms.
More guides for patients in the District of Columbia
Related
- Weight care in the District of Columbia
- GLP-1 medication access in the District of Columbia
- Semaglutide in the District of Columbia
Other care areas
At a glance
| Company | On this page | Lowest listed monthly figure | Checked | Official site |
|---|---|---|---|---|
| Gentle Health | Compounded injectable tirzepatide | $169/mo advertised monthly bundle, Compounded injectable tirzepatide | Official site ↗ |
Selected providers
Which providers offer Tirzepatide in the District of Columbia?
1 companies with published profiles and service-specific source records. Listed alphabetically, not ranked. This is selected coverage—not every provider in the market.
Formats describe the program, not a guaranteed first-visit option in every state. A messaging or questionnaire option does not promise an initial evaluation without a live appointment. Read each provider’s service and state access notes.
The monthly cost column adds disclosed medication and required membership charges at each advertised dose and labels each figure an advertised bundle or a known subtotal. Where labs, taxes or other charges are not priced, the figure is not a guaranteed final bill. Cash prices use each provider’s stated monthly billing basis; supplied weeks and upfront commitments can differ. Dose labels identify price tiers, not treatment recommendations.
| Company & service | Program formats & clinicians | Payment & advertised charges | Monthly cost by dose | Access & evidence |
|---|---|---|---|---|
| Gentle Health Gentle Health's compounded injectable tirzepatide program, if prescribed, billed through its medication-order subscription.
Medical Director: James Simmons, MD — company-reported; see profile for the source. |
Gentle Health describes physician evaluation with online intake and live-visit arrangements. A coverage listing does not establish approval, an appointment slot or pharmacy stock. Access channel: Direct to consumer | Cash pay Advertised monthly tirzepatide tiers are $169, $219 and $269, without a separate membership charge. Current terms allow cancellation before pharmacy submission or beginning 30 days after the order date once submitted. | Compounded injectable tirzepatide · injection Advertised monthly bundle
Medication, physician reviews, messaging/video visits and delivery; the company advertises no membership fee or added tax. Not priced: Patient-specific laboratory testing is not priced on the reviewed pages. Billing and introductory offersMonthly subscription price. Current terms allow cancellation before pharmacy submission or beginning 30 days after the order date once submitted; cancellation stops future billing without refunding the current billing month's remainder. Price check: . Gentle Health — services, price table and frequently asked questions · Gentle Health — Terms of Service | Compounded injectable tirzepatide — injection: Company-reported District of Columbia coverage for the named compounded injectable tirzepatide program. The company's workflow article places Washington, DC in its asynchronous-start group, so the first visit is described as a reviewed questionnaire rather than a scheduled video call. A clinician may still request a live conversation. Coverage does not establish individual approval, pharmacy eligibility or stock. The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including District of Columbia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. State evidence checked · Product state availability source This is compounded injectable tirzepatide, not branded Zepbound or Mounjaro. The company's coverage article reports it across 40 states plus DC and names Missouri as the newest addition on September 18. Its Missouri detail page was still being added when rechecked. Individual eligibility and fulfillment remain unverified. Company-reported · Checked
|
No providers match these filters. Try a different payment model or program format.
How companies enter this list
Each listed product has separately reviewed, current product-specific evidence for this state. A company footprint or broad care service cannot establish medication access. Named products, forms and approval categories remain distinct; inclusion is not a claim of interchangeability. The list is selective, not a complete inventory of providers. Inclusion does not establish clinical suitability, state licensure or a currently available appointment.
Smaller and larger providers use the same source requirements and alphabetical ordering. Visit each profile for company history and wider context, or suggest another provider.
Source documents
The table dates show when its claims were checked. Document dates below describe the original sources, where supplied. Additional sources are linked directly in the guide.
- Zepbound — Product labeling on DailyMed — Eli Lilly and Company; hosted by the U.S. National Library of Medicine
- FDA — Concerns with unapproved GLP-1 drugs — U.S. Food and Drug Administration
- FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — U.S. Food and Drug Administration
- Gentle Health — services, price table and frequently asked questions — Gentle Health
- Gentle Health — states served and expansion account — Gentle Health; published
- Gentle Health — Connecticut GLP-1 weight-loss service page — Gentle Health
- Gentle Health — Vermont GLP-1 weight-loss service page — Gentle Health
- Gentle Health — Terms of Service — Gentle Health
- How Gentle Health's Initial Prescribing Process Varies by State — Gentle Health; published